Business Context and Reporting Period
This Form 8-K Current Report was filed by Aptevo Therapeutics Inc. on December 14, 2020. The filing reports the entry into a Material Definitive Agreement regarding an equity distribution program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new financing agreement.
Material Changes
On December 14, 2020, the Company entered into an Equity Distribution Agreement with Piper Sandler & Co. This agreement establishes an "at-the-market" offering program allowing the Company to issue and sell shares of its common stock through Piper Sandler acting as a sales agent. The Company has no obligation to sell any shares under this agreement.
Guidance, Outlook, and Risks
- Agreement Terms: Sales are subject to a Registration Statement on Form S-3 filed on December 14, 2020. The Company controls sales parameters via "Placement Notices," including share count, time period, daily limits, and minimum price.
- Compensation: Piper Sandler is entitled to a commission of 3.0% of the gross proceeds from each placement.
- Termination: The agreement terminates upon the sale of all shares or earlier by notice from either party. No shares may be sold after three years from the effective date of the Registration Statement.
- Risks: The filing includes standard disclaimers that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement filed on December 14, 2020.
- Monitor future filings for "Placement Notices" to track actual share issuance volumes and pricing.
- Review the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific conditions and termination rights.
- Assess the impact of the 3.0% sales commission on net proceeds from future capital raises.